J&J's Carvykti succeeds in late-stage trial for a type of blood cancer

- Johnson & Johnson said on Friday its cancer drug, Carvykti, met the main goal of a late-stage study for treating patients with a type of myeloma, according to an interim analysis.

(Reporting by Raghav Mahobe in Bengaluru; Editing by Vinay Dwivedi)